Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema

NCT06850922 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT06850922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06850922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema
Lead sponsor
Genentech, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 22, 2022
Completion date
June 19, 2026
Enrollment
388 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema